Bulk RNA-seq of 32 pre-TKI and 42 post-TKI treated (osimertinib/erlotinib/crizotinib/alectinib) clinical tumor samples revealed a significant increase of A3B expression post-TKI relative to pre-TKI samples (P = 0.011; Fig. 7a). This evidence concerns the gene APOBEC3B and neoplasm.